Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The purpose of this study is to evaluate the safety, tolerability, immunogenicity, and pharmacodynamic effects of ACI-7104.056 in patients with early stages of Parkinson's disease.
Full description
This is a Phase 2, multicenter, placebo-controlled, double-blind, randomized study with adaptive features, comprising a screening period of up to 8 weeks, a 74-week double-blind treatment period, and a 26-week post-treatment follow-up period in study Part 1 and 2. One cohort from study Part 1 may enter an extension phase including a rescreening period of up to 4 weeks, a 52-week double-blind treatment period, and a 26-week post-treatment follow-up period.
Study Part 1 may include up to 3 cohorts, each consisting of up to 32 participants (up to 24 under the active treatment and up to 8 under placebo; 3:1 active treatment/placebo ratio). One of the cohorts from study Part 1 may be further expanded into study Part 2 to reach an overall total of up to 150 participants in the study. If a cohort is further expanded beyond 32 participants into study Part 2, the active treatment/placebo ratio will be adjusted to reach a 2:1 ratio in this cohort.
The route of administration of the study treatment and placebo will be by intramuscular injections.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion criteria for study Part 1 and Part 2:
Exclusion criteria for study Part 1 and Part 2:
Medical history indicating a Parkinsonian syndrome other than idiopathic PD, including but not limited to, progressive supranuclear palsy, multiple system atrophy, drug induced parkinsonism, essential tremor, vascular parkinsonism, primary dystonia.
Known carriers of certain familial PD gene mutations (PRKN, PINK1, DJ1, LRRK2).
History of PD-related freezing episodes or falls.
History of brain surgery or any neurosurgical procedures.
Reside in a nursing home or assisted care facility.
A history of cancer within 5 years of baseline with the exception of fully excised non melanoma skin cancers or nonmetastatic prostate cancer that has been stable for at least 6 months, or cervical intraepithelial neoplasia stage I uterine cancer.
History of and/or screening brain MRI scan indicative of, clinically significant abnormality including but not limited to prior hemorrhage or infarct >1 cm3 or >3 lacunar infarcts.
Diagnosis of a significant central nervous system disease other than PD (including but not limited to Huntington's disease, normal pressure hydrocephalus, cerebrovascular disease including stroke, fronto-temporal dementia, Alzheimer's disease, dementia with Lewy bodies, multiple sclerosis, brain tumor); history of repeated head injury; history of epilepsy or seizure disorder other than febrile seizures as a child.
Presence of psychiatric symptoms (eg, confusion, hallucination, delusion, excitation, delirium, abnormal behavior at screening and baseline). Note: mild depression, depressive mood, or mild anxiety arising in the context of PD are not exclusionary.
Clinically significant concomitant disease or condition within 6 months prior to screening, or as specified below, that could interfere with the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to the study participant:
Current, or history of, alcohol or drug (including cannabis) abuse or other dependence (except nicotine dependence) within 12 months before screening.
Participants with known hypersensitivity to the study treatment or placebo components.
Participants who previously received a vaccination (ie, influenza treatment and COVID 19) within the last 4 weeks prior to randomization or standard-of-care immunizations within the last 2 weeks prior to randomization.
Participants being treated with any anticoagulants or antiplatelet drugs, except aspirin at doses of 100 mg daily or lower.
Inclusion criteria for the extension of study Part 1:
Exclusion criteria for the extension of study Part 1:
Exclusion criteria for the study Part 1 and Part 2 are applicable and should be reassessed for Extension of study Part 1 relative to the rescreening period, with the following exceptions:
Primary purpose
Allocation
Interventional model
Masking
150 participants in 4 patient groups, including a placebo group
Loading...
Central trial contact
Tanja Touilloux; Olivier Sol
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal